Dominant-negative suppression of HNF-1 alpha results in mitochondrial dysfunction, INS-1 cell apoptosis, and increased sensitivity to ceramide-, but not to high glucose-induced cell death

WOBSER, Hella, et al.

Abstract
Maturity onset diabetes of the young (MODY) 3 is a monogenic form of diabetes caused by mutations in the transcription factor hepatocyte nuclear factor (HNF)-1 alpha. We investigated the involvement of apoptotic events in INS-1 insulinoma cells overexpressing wild-type HNF-1 alpha (WT-HNF-1 alpha) or a dominant-negative mutant (DN-HNF-1 alpha) under control of a doxycycline-dependent transcriptional activator. Forty-eight h after induction of DN-HNF-1 alpha, INS-1 cells activated caspase-3 and underwent apoptotic cell death, while cells overexpressing WT-HNF-1 alpha remained viable. Mitochondrial cytochrome c release and activation of caspase-9 accompanied DN-HNF-1 alpha-induced apoptosis, suggesting the involvement of the mitochondrial apoptosis pathway. Activation of caspases was preceded by mitochondrial hyperpolarization and decreased expression of the anti-apoptotic protein Bcl-xL. Transient overexpression of Bcl-xL was sufficient to rescue INS-1 cells from DN-HNF-1 alpha-induced apoptosis. Both WT- and DN-HNF-1 alpha-expressing cells demonstrated similar increases in apoptosis when cultured at high glucose (25 mm). [...]
Dominant-negative Suppression of HNF-1α Results in Mitochondrial Dysfunction, INS-1 Cell Apoptosis, and Increased Sensitivity to Ceramide-, but Not to High Glucose-induced Cell Death*

Received for publication, August 30, 2001, and in revised form, October 30, 2001
Published, JBC Papers in Press, November 27, 2001, DOI 10.1074/jbc.M105890200

Hella Wobser‡, Heiko Düßmann‡, Donat Kögel‡, Haiyan Wang§, Claus Reimertz‡,
Claes B. Wollheim§, Maria M. Byrne¶, and Jochen H. M. Prehn‡,**

From the ‡Interdisciplinary Center for Clinical Research (IZKF), Research Group “Apoptosis and Cell Death,” the
¶Department of Pharmacology and Toxicology, Westphalian Wilhelms-University, D-48149 Münster, Germany, and the
§Department of Internal Medicine, Division of Clinical Biochemistry and Experimental Diabetology, University Medical Center,
CH-1211 Geneva, Switzerland

Maturity onset diabetes of the young (MODY) is a monogenic form of diabetes caused by mutations in the transcription factor hepatocyte nuclear factor (HNF)-1α. We investigated the involvement of apoptotic events in INS-1 insulinoma cells overexpressing wild-type HNF-1α (WT-HNF-1α) or a dominant-negative mutant (DN-HNF-1α) under control of a doxycycline-dependent transcriptional activator. Forty-eight h after induction of DN-HNF-1α, INS-1 cells activated caspase-3 and underwent apoptotic cell death, while cells overexpressing WT-HNF-1α remained viable. Mitochondrial cytochrome c release and activation of caspase-9 accompanied DN-HNF-1α-induced apoptosis, suggesting the involvement of the mitochondrial apoptosis pathway. Activation of caspases was preceded by mitochondrial hyperpolarization and decreased expression of the anti-apoptotic protein Bcl-xL. Transient overexpression of Bcl-xL was sufficient to rescue INS-1 cells from DN-HNF-1α-induced apoptosis. Both WT- and DN-HNF-1α-expressing cells demonstrated similar increases in apoptosis when cultured at high glucose (25 mM). In contrast, induction of DN-HNF-1α highly sensitized cells to ceramide toxicity. In cells cultured at low glucose, DN-HNF-1α induction also caused up-regulation of the cell cycle inhibitor p27KIP1. Therefore, our data indicate that increased sensitivity to the mitochondrial apoptosis pathway and decreased cell proliferation may account for the progressive loss of β-cell function seen in MODY 3 subjects.

Maturity onset diabetes of the young (MODY) is a monogenic form of diabetes characterized by early age of onset (<25 years), autosomal dominant transmission, and primary pancreatic β-cell dysfunction (1). It has been postulated that it may account for ~1–5% of all diabetes. It results from heterozygous mutations of at least six different genes, one encoding for the glycolytic enzyme glucokinase (MODY2) and the others encoding transcription factors hepatocyte nuclear factor (HNF)-4α (MODY1), HNF-1α (TCF1; MODY3), insulin promoter factor-1 (IPF-1; MODY4), HNF-1β (TCF2; MODY5), and NeuroDβ2 (MODY6). MODY3 is the commonest form of MODY accounting for 65% of MODY cases in the United Kingdom (2).

Phenotypically, most MODY 3 subjects under the age of 10 years have normal glucose tolerance (2). However, studies in the prediabetic phase show that insulin secretion is reduced only when plasma glucose concentrations exceed 8 mm (3). Similar patterns of insulin secretion are seen in MODY 1 subjects (4) as well as in partially pancreatectomized rats and dogs (5, 6) suggesting that a reduction in β-cell mass may be contributing to the observed β-cell dysfunction.

HNF-1α is a dimeric homeodomain-containing protein that is expressed in the liver, kidney, intestine, and pancreatic islets (7–9). It is involved in the regulation of hepatic proteins as well as proteins affecting carbohydrate metabolism and fatty acid homeostasis (10–13). HNF-1α gene mutations are found in the promoter region, DNA-binding domain, and transactivation domain, and lead to a loss of function. Some mutants such as the most frequently found P291fsinsC also act as dominant-negative proteins in vitro, i.e. they retain their DNA-binding domain and form nonfunctional dimers with wild-type HNF-1α (14, 15). Considerable variation also exists in the severity of the diabetes (2, 16), with ~30% of MODY3 subjects eventually requiring insulin therapy.

Homozygous HNF-1α knockout mice develop diabetes with defective insulin secretary responses to glucose and arginine (11, 12) but normal responses to KCl (17). These mice also demonstrated an inadequate β-cell mass for the degree of hyperglycemia, as well as a reduction in the ratio of β- to non-β cells. Principally, a defect in β-cell mass compensation can be caused by decreased neogenesis/proliferation rate, increased apoptosis rate, or both (18). Reduction in β-cell mass has been observed in several NIDDM animal models (19–24). There is strong evidence supporting the increase in β-cell apoptosis as a predominant factor resulting in decrease in β-cell mass (19, 21, 25–27).

This study was therefore undertaken to establish whether HNF-1α function plays a role in the control of apoptosis in insulin secreting cells, and thereby the pathogenesis of MODY3 diabetes. This study demonstrates that dominant-negative
suppression of HNF-1α function in INS-1 insulinoma cells activates the evolutionary conserved apoptotic cell death machinery via alterations in gene expression and mitochondrial function, and increases their sensitivity to ceramide, but not ery, via alterations in gene expression and mitochondrial function (0°C treatment was performed in the presence of varying glucose concentrations). The level of HNF-1α high glucose-induced apoptosis, and increases their sensitivity to ceramide-, but not ery via alterations in gene expression and mitochondrial function (0°C treatment was performed in the presence of varying glucose concentrations). The level of HNF-1α high glucose-induced apoptosis, and increases their sensitivity to ceramide-, but not ery via alterations in gene expression and mitochondrial function (0°C treatment was performed in the presence of varying glucose concentrations).

**EXPERIMENTAL PROCEDURES**

**Materials—N-Acetyl-b-erythrosphingosine (C2-ceramide) and stau-**

**nol/acetic acid at 10 min, then permeabilized by treatment with a 19:1 mixture of etha-**

**nerescent units (A.U.) per 380 nm, emission 465 nm). Fluorescence of blanks containing no cell**

**fluence was detected using the Fluoview 2.0 software and Kalman averaged from two individual scans for each time point. After background subtraction the fluorescence intensity of J-aggregates (570 nm) was devided by the intensity of the J-1 monomers (510–540 nm) for each image. Quantitative analysis of the images was performed using the UTHSCSA Image Tool Program (available from www.maxrad6.uthscsa.edu).**

**Detection of Cytochrome c Release—Selective plasma membrane per-**

**meabilization with digitonin was used to analyze the release of cyto-**

**chrome c from mitochondria into the cytosol (32). This method obviates possible artifacts due to mechanical breakage of the outer mitochon-**

**drial membrane. Cultured cells were incubated in 0.1% (v/v) doxycy-**

**cline for 8 h at the indicated glucose concentrations. Total RNA was extracted by the guanidinium isothiocyanate/phenol/chloroform method. Total RNA (20 μg) was denatured with glyosulfate and dimethyl sulfoxide and separated on 1% agarose gels. Resolved RNA was blotted on nylon membranes (Hybond-N, Amersham Pharmacia Biotech) by vacuum transfer (VacuGeneXL, Amersham Pharmacia Biotech), followed by UV cross-linking. The membranes were prehybridized and then hybridized to 32P-labeled random primed cDNA probes according to the manufacturer’s instructions using probes for cytochrome c, Bcl-XL, Bax, Bad, Bid, p21, and p27 mRNA detection were prepared by reverse transcriptase-PCR and confirmed by sequencing. HNF-1α cDNA was obtained from corresponding expression vector kindly provided by Dr. R. Cortese (Istituto Di Ricerca Di Biologica Molecolare, Pomezia, Italy).

**Western Blotting—Cells were rinsed with ice-cold PBS and subsequently incubated in 100 μl of permeabilization buffer (210 mM t-mannitol, 70 mM sucrose, 10 mM HEPES, 5 μm succinate, 0.2 mM EGTA, 100 μg/ml digitonin, pH 7.2) for 5 min. The permeabilization buffer was transferred to a reaction tube and centrifuged for 10 min at 13,000 × g. The supernatant was transferred to a new reaction tube and protein content was determined using the Pierce BCA Micro Protein Assay kit. Equal amounts of protein were analyzed by Western blot analysis using 15% SDS-PAGE as described below.**

**Total RNA Extraction and Northern Blot Analysis—DN-HNF1α cells were cultured in the presence or absence of 500 ng/ml doxycycline for 48 h and continued for 8 h at the indicated glucose concentrations. Total RNA was extracted by the guanidinium isothiocyanate/phenol/chloroform method. Total RNA (20 μg) was denatured with glyosulfate and dimethyl sulfoxide and separated on 1% agarose gels. Resolved RNA was blotted on nylon membranes (Hybond-N, Amersham Pharmacia Biotech) by vacuum transfer (VacuGeneXL, Amersham Pharmacia Biotech), followed by UV cross-linking. The membranes were prehybridized and then hybridized to 32P-labeled random primed cDNA probes according to the manufacturer’s instructions using probes for cytochrome c, Bcl-XL, Bax, Bad, Bid, p21, and p27 mRNA detection were prepared by reverse transcriptase-PCR and confirmed by sequencing. HNF-1α cDNA was obtained from corresponding expression vector kindly provided by Dr. R. Cortese (Istituto Di Ricerca Di Biologica Molecolare, Pomezia, Italy).

**Western Blotting—Cells were rinsed with ice-cold PBS and lysed in T-PER with sodium containing SDS, glycine, and protease inhibitors. Protein content was determined using the Pierce BCA Micro Protein Assay kit. Samples were supplemented with 2-mercaptoethanol and denatured at 95°C for 5 min. An equal amount of protein (20–50 μg) was separated with 5–15% SDS-PAGE and blotted to nitrocellulose membranes (Protan BA 85; Schleicher & Schuell, Dassel, Germany).**

The Western blotting was performed using a rabbit polyclonal anti-HNF-1α antibody (clone TH8:2C12, 1:1,000, Pharmingen Beckton Dickinson, Hamburg, Germany), a rabbit polyclonal anti-active caspase-3 antibody (MF445) raised against the p18 large subunit diluted 1:1,000 (kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quee- beam, Canada), a rabbit polyclonal anti-active caspase-9 antibody (MF445) raised against the p18 large subunit diluted 1:1,000 (kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada), a rabbit polyclonal anti-active caspase-9 antibody (MF445) raised against the p18 large subunit diluted 1:1,000 (kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada), a rabbit polyclonal anti-active caspase-9 antibody (MF445) raised against the p18 large subunit diluted 1:1,000 (kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada). The blot was blocked with 5% nonfat milk in blocking solution (15% Tris-HCl, pH 7.5, 200 μM NaCl, and 0.1% Tween 20) for 2 h at room temperature. Membranes were incubated overnight at 4°C with the following primary antibodies: a rabbit polyclonal anti-HNF-1α antibody diluted 1:5,000 (kindly provided by Dr. R. Cortese), a mouse monoclonal anti-cytochrome c antibody (clone TH8:2C12, 1:1,000, Pharmingen Beckton Dickinson, Hamburg, Germany), a rabbit polyclonal anti-active caspase-3 antibody (MF97) raised against p17/p12 x-ray crystallographic grade recombinant caspase-3 diluted 1:1,000 (33) kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada), a rabbit polyclonal anti-active caspase-9 antibody (MF445) raised against the p18 large subunit diluted 1:1,000 (kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada), a rabbit polyclonal anti-active caspase-9 antibody (MF445) raised against the p18 large subunit diluted 1:1,000 (kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada). The blot was blocked with 5% nonfat milk in blocking solution (15% Tris-HCl, pH 7.5, 200 μM NaCl, and 0.1% Tween 20) for 2 h at room temperature. Membranes were incubated overnight at 4°C with the following primary antibodies: a rabbit polyclonal anti-HNF-1α antibody diluted 1:5,000 (kindly provided by Dr. R. Cortese), a mouse monoclonal anti-cytochrome c antibody (clone TH8:2C12, 1:1,000, Pharmingen Beckton Dickinson, Hamburg, Germany), a rabbit polyclonal anti-active caspase-3 antibody (MF97) raised against p17/p12 x-ray crystallographic grade recombinant caspase-3 diluted 1:1,000 (33) kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada), a rabbit polyclonal anti-active caspase-9 antibody (MF445) raised against the p18 large subunit diluted 1:1,000 (kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada), a rabbit polyclonal anti-active caspase-9 antibody (MF445) raised against the p18 large subunit diluted 1:1,000 (kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada), a rabbit polyclonal anti-active caspase-9 antibody (MF445) raised against the p18 large subunit diluted 1:1,000 (kindly provided by Dr. W. Nicholson, Merck Frosst, Point Claire-Dorval, Quebec, Canada).
Fig. 1. Induction of DN-HNF-1α induces apoptosis in INS-1 cells. Time course of induction of WT-HNF-1α (A) and DN-HNF-1α (B) in response to 500 ng/ml doxycycline. Fifty µg of protein extract was separated by 10% SDS-PAGE, proteins were blotted, and immunodetection was performed using an anti-HNF-1α antibody. Locations of molecular weight marker bands (in kDa) are provided on the left side of the figure. Membranes were stripped and reprobed with an anti-α-tubulin antibody. Phase-contrast images and corresponding Hoechst 33258 staining of nuclei in INS-1 cells induced to express WT-HNF-1α (C) or DN-HNF-1α (D) for 0, 24, and 48 h. Non-induced controls show a smooth cell surface and a septate pattern of blue Hoechst fluorescence. Note cell shrinkage, membrane blebbing, and chromatin condensation and fragmentation in cells overexpressing DN-HNF-1α. Scale bar = 10 µm.

RESULTS

INS-1 Cells Subjected to Prolonged Suppression of HNF-1α Function Undergo Apoptotic Cell Death—Using a reverse tetracycline-dependent transactivator system we have previously shown that dominant-negative suppression of HNF-1α function inhibits the expression of HNF-1α target genes involved in glucose and lipid homeostasis (15, 28). In subsequent experiments, we noted that under conditions of prolonged induction of DN-HNF-1α (>48 h), INS-1 cells frequently detached from the substratum and floated in the culture medium. Floating cells exhibited a round, shrunken morphology reminiscent of apoptosis, suggesting that dominant-negative suppression of HNF-1α may have also influenced the expression of genes involved in the regulation of apoptosis. To investigate the relationship between induction of DN-HNF-1α and alterations in cell morphology in more detail, expression of WT-HNF-1α and DN-HNF-1α was induced in INS-1 cells by treatment with doxycycline for 6, 14, 24, 48, and 60 h. Apoptotic cell morphology was assessed in parallel by Hoechst staining of nuclear chromatin. Treatment with 500 ng/ml doxycycline led to a rapid induction of WT-HNF-1α and DN-HNF-1α in INS-1 cells stably transfected with the reverse tetracycline-dependent transactivator system, displaying similar kinetics (Fig. 1, A and B). In each case, significant induction was already evident after 14 h of doxycycline treatment. Nuclei of non-induced control cells exhibited a regular, oval shape and a septate pattern of blue fluorescence (Fig. 1, C and D). The nuclear morphology of INS-1 cells remained unchanged at 6 and 14 h after induction of DN-HNF-1α (not shown). Twenty-four h after doxycycline treatment, the majority of cells induced to overexpress DN-HNF-1α also displayed regular nuclear Hoechst staining and a normal cell morphology (Fig. 1D). Occasionally, however, we detected cells with a typical nuclear apoptotic morphology characterized by increased chromatin condensation and nuclear fragmentation. By 48 h, apoptotic nuclear changes became visible in many DN-HNF-1α-expressing INS-1 cells. By 60 h, non-apoptotic, apoptotic, late-stage apoptotic/enucleated cells, as well as floating cells could be detected in the cultures (not shown). Induction of WT-HNF-1α for 24, 48, or 60 h, in contrast, did not lead to any significant changes in nuclear morphology (Fig. 1C and data not shown). These re-
Results suggested that prolonged, dominant-negative suppression of HNF-1α function is sufficient to trigger apoptosis in INS-1 cells.

Apoptotic Cell Death Induced by Dominant-negative Suppression of HNF-1α Function Involves Activation of Executioner Caspases—Caspases play a central role in the activation and execution of apoptotic cell death. Based on their structure and substrate specificity, caspases can be subdivided into three subfamilies: (i) upstream or apical caspases containing a large NH₂-terminal region and specific motifs that are required for their aggregation and autoactivation; (ii) downstream or effector caspases that are responsible for the execution of apoptotic cell death; and (iii) caspases involved in the maturation of pro-inflammatory cytokines (36). To assess whether activation of executioner caspases was involved in DN-HNF-1α-induced cell death, we measured caspase activity by monitoring the cleavage of a fluorogenic caspase substrate by extracts from doxycycline-treated INS-1 cells. Ac-DEVD-AMC is cleaved most efficiently by caspase-3, the major executioner caspase in most cell types, but also by other executioner caspases (30). Production of the fluorescent cleavage product AMC was negligible with extracts from non-induced INS-1 cells containing 3.55 ± 0.35 A.U./μg of protein and h. By 48 h, caspase activity reached a maximum of 33.71 ± 0.86 A.U./μg of protein and h, an ~10-fold increase compared with non-induced control. Cleavage activity remained elevated at 60 h of doxycycline treatment. In contrast, induction of WT-HNF-1α for up to 60 h did not cause significant caspase activity in the cultures (Fig. 2A), at any time point. Parental INS-1 cells exposed to doxycycline also failed to exhibit any increase in cleavage activity (Fig. 2A).

We also obtained direct evidence of caspase-3 activation by Western blotting experiments. During apoptosis, caspase-3 is proteolytically activated by cleavage of its 32-kDa precursor into active subunits. We observed the appearance of the active p17 subunit during the induction of DN-HNF-1α (Fig. 2B). In contrast, the p17 subunit could not be detected after induction of WT-HNF-1α (Fig. 2B). Both cell lines, however, were able to activate caspase-3 in response to the apoptosis-inducing protein kinase inhibitor, STS, a potent pro-apoptotic stimulus (Fig. 2B).

Further evidence for the involvement of caspases in DN-HNF-1α-induced apoptosis was provided by examining the effect of the broad-spectrum caspase inhibitor, zVAD-fmk. A simultaneous treatment with 100 μM zVAD-fmk potently inhibited nuclear fragmentation examined 48 h after the induction of DN-HNF-1α (Fig. 2, C and D).

Activation of the Mitochondrial Apoptosis Pathway in DN-HNF-1α-Induced Apoptosis: Mitochondrial Hyperpolarization Precedes Cytochrome c Release—The release of pro-apoptotic factors, such as cytochrome c, from the mitochondrial intermembrane space into the cytosol represents a central coordinating step in apoptosis (37). Cytoplasmic accumulation of pro-apoptotic cytochrome c induces a caspase activating, multiprotein complex, the apoptosome (38, 39). Evidence has been provided that mitochondrial hyperpolarization is an early event in trophic factor deprivation-, UV-, and STS-induced apoptosis, preceding the release of pro-apoptotic factors such as cytochrome c from mitochondria (40–44). We used the potential-sensitive probe JC-1 in combination with confocal laser scanning microscopy to evaluate changes in mitochondrial membrane potential during DN-HNF-1α-induced apoptosis. Twenty-four h after addition of doxycycline, mitochondrial hyperpolarization could be detected in the majority of INS-1 cells, preceding the gross activation of executioner caspases (Fig. 3, A and B). After 48 h of induction, cells with shrunken somata and depolarized mitochondria could also be detected (Fig. 3A). This finding is in agreement with previous studies showing that mitochondria eventually depolarize after the release of cytochrome c and activation of the caspase cascade (41, 45, 46). The mitochondrial membrane potential of cells induced to overexpress WT-HNF-1α did not change significantly up to 60 h after onset of the doxycycline treatment (data not shown).

Mitochondrial hyperpolarization after induction of DN-HNF-1α was followed by the release of the pro-apoptotic factor cytochrome c from mitochondria (Fig. 3C). Using selective digitonin permeabilization of the plasma membrane, cytosolic accumulation of cytochrome c could be detected after 48 and 60 h of doxycycline treatment. No significant cytochrome c release could be detected in cells expressing WT-HNF-1α. After its release into the cytosol, cytochrome c is capable of binding to the apoptotic protease-activating factor 1 (39). This complex activates procaspase-9 in the presence of dATP, resulting in apoptosome formation and activation of executioner caspases such as caspase-3 (38, 39). In agreement with previous reports demonstrating significant autoactivation of procaspase-9 even in unstimulated cells (47), non-induced controls exhibited detectable levels of the active, large p18 subunit of caspase-9 (Fig. 3D). Induction of DN-HNF-1α led to significant accumulation of...
the p18 active subunit after 48 and 60 h, while cells overexpressing WT-HNF-1α did not show such an increase (Fig. 3D).

Altered Gene Expression of Bcl-xL and p27KIP1 during Dominant-negative Suppression of HNF-1α Function—Release of pro-apoptotic factors from mitochondria requires a selective outer membrane permeability increase that is triggered and controlled by pro- and anti-apoptotic Bcl-2 family proteins (37).

We next investigated the expression of Bcl-2 family members during DN-HNF-1α-induced apoptosis. Bax is a pro-apoptotic Bcl-2 family member believed to be a structural component of the mitochondrial outer membrane release channel (37). Expression of bax mRNA was not altered 48 h after induction of DN-HNF-1α (Fig. 4A). Moreover, bax gene expression was not sensitive to alterations in glucose concentration, both in induced and non-induced cells. Bax protein levels also remained unchanged, and similar results were obtained with the pro-apoptotic Bax homolog Bak (data not shown). Nevertheless, we obtained evidence for Bax activation during DN-HNF-1α-induced apoptosis detected with a polyclonal antibody that recognizes a conformational change in Bax required for its pro-apoptotic activity. INS-1 cells were induced to overexpress DN-HNF-1α-1e in the presence of 12 mM glucose for 48 h or were exposed to 3 μM STS for 6 h. C, decrease in Bcl-xL protein expression during DN-HNF-1α-induced apoptosis detected by immunofluorescence analysis using a monoclonal antibody. INS-1 cells were induced to overexpress WT- or DN-HNF-1α for 48 h in the presence of 12 mM glucose, both in the absence or presence of the caspase inhibitor zVAD-fmk (100 μM). Scale bar = 10 μm.

We next investigated the expression of Bcl-2 family members during DN-HNF-1α-induced apoptosis. Bax is a pro-apoptotic Bcl-2 family member believed to be a structural component of the mitochondrial outer membrane release channel (37). Expression of bax mRNA was not altered 48 h after induction of DN-HNF-1α (Fig. 4A). Moreover, bax gene expression was not sensitive to alterations in glucose concentration, both in induced and non-induced cells. Bax protein levels also remained unchanged, and similar results were obtained with the pro-apoptotic Bax homolog Bak (data not shown). Nevertheless, we obtained evidence for Bax activation during DN-HNF-1α-induced apoptosis detected with a polyclonal antibody that recognizes a conformational change in Bax required for its pro-
apoptotic activity (Fig. 4B) (34). Bax activation could also be detected in response to 3 μM STS (Fig. 4B).

Of note, expression of the anti-apoptotic Bcl-2 family member Bcl-xL decreased significantly after DN-HNF-1α induction (Fig. 4A). Bcl-xL mRNA expression was regulated by glucose in induced and non-induced cultures, with increasing levels at increasing glucose concentrations. However, DN-HNF-1α-expressing cells showed a decreased response to glucose for Bcl-xL mRNA expression compared with non-induced cells. The decrease in Bcl-xL expression upon induction of DN-HNF-1α could also be detected on the protein level (Fig. 4C). Cultures treated with the caspase inhibitor zVAD-FMK also showed this decrease, suggesting that this was not due to caspase-mediated degradation of Bcl-xL (48). Cells expressing WT-HNF-1α did not exhibit a decrease in Bcl-xL expression (Fig. 4C).

We next investigated the expression of pro-apoptotic Bcl-2 family members of the Bcl-2-homology domain BH3-only family during the induction of DN-HNF-1α. These proteins are believed to neutralize the anti-apoptotic activity of Bcl-2 and Bcl-xL via direct protein-protein interactions, hence sensitizing cells to Bax- or Bak-mediated cytochrome c release (49). The expression of the BH3-only members Bad, Bid, and Bim remained unchanged during the induction of DN-HNF-1α (Fig. 4A and data not shown). However, by a screen of other genes involved in cell cycle and apoptosis regulation, we found that induction of DN-HNF-1α also led to a dramatic increase in the expression of the cell cycle inhibitor p27KIP1, most notable at low glucose concentrations (Fig. 4A). Expression of p21WAF1, a second cell cycle inhibitor and an important p53 target gene, was slightly increased at the highest glucose concentration. However, induction of DN-HNF-1α did not potentiate p21WAF1 mRNA expression.

**Overexpression of Bcl-xL Is Sufficient to Inhibit Apoptosis Induction by DN-HNF-1α**—Evidence has been provided that Bcl-xL inhibits cytochrome c release during apoptosis (40). We were therefore interested to determine whether overexpression of Bcl-xL was able to reverse DN-HNF-1α-induced cell death. INS-1 cells were transfected with plasmids encoding an EGFP-Bcl-xL fusion protein or EGFP alone (controls). Twenty-four h after the transfection, expression of DN-HNF-1α was induced for time periods of 48 and 60 h. Cells were assessed for apoptosis by counterstaining with Hoechst 33258 and analyzed by epifluorescence and phase contrast microscopy. Note the absence of chromatin condensation and fragmentation in cells expressing Bcl-xL-EGFP. Scale bar = 20 μm. B, quantitative analysis of nuclear apoptosis in Bcl-xL-EGFP- and EGFP-transfected INS-1 cells induced to overexpress DN-HNF-1α for 48 or 60 h. Non-induced cells served as controls. All GFP-positive cells per culture (~100 cells) were assessed for apoptotic nuclear morphology. Data are mean ± S.E. from n = 5–6 cultures in three separate transfection experiments. Different from respective non-induced controls: *p < 0.05. Difference between Bcl-xL-EGFP- and EGFP-transfected cultures: #, p < 0.05.

However, the increase in apoptosis was potentiated in DN-HNF-1α-expressing cells. Exposure to high glucose (17.5 and 25 mm) did not induce apoptosis in either cell line.

In a second experiment, expression of WT- and DN-HNF-1α was induced for 48 h (Fig. 6A). Cells overexpressing WT-HNF-1α showed increased apoptosis at 0 and 25 compared with 5 and 10 mM glucose. DN-HNF-1α expressing cells showed significantly higher apoptosis activation at 2, 5, 10, and 17.5 mM glucose compared with WT-HNF-1α-expressing cells. However, there was no statistically significant difference in the extent of apoptosis induction by 25 mM glucose between WT- and DN-HNF-1α-expressing cells. DN-HNF-1α-expressing cells cultured at 0 mM glucose could not be analyzed after 48 h, since most cells had already detached from the culture dish.

Ceramide toxicity has been shown to mediate fatty acid-induced apoptosis in β-cells (25, 50). We finally investigated the effect of an exposure to C2-ceramide in WT- and DN-HNF-1α-expressing INS-1 cells (Fig. 6B). Cells were induced to express WT- or DN-HNF-1α for 14 and 24 h. During the last 4 h, cells were treated with 50 or 100 μM C2-ceramide, and a caspase activity assay was performed. Interestingly, exposure to 100 μM C2-ceramide potently activated apoptosis in the cells overexpressing DN-HNF-1α for 24 h. Pronounced activation of caspases could already be detected in C2-ceramide-treated cultures induced to overexpress DN-HNF-1α for 14 h. In contrast, C2-ceramide only induced a very modest caspase activation in cells overexpressing WT-HNF-1α for 24 h.
Dominant-negative HNF-1α Induces Apoptosis

The present study demonstrates several important findings that may help in the understanding of β-cell dysfunction in subjects with MODY3. These include (i) prolonged suppression of HNF-1α function is sufficient to activate the evolutionary conserved apoptotic cell death program in insulin-secreting cells; (ii) overexpression of DN-HNF-1α leads to decreased expression of the central survival protein Bcl-xL; (iii) sensitizes the cell to ceramide-, but not to high glucose-induced apoptosis; and (iv) leads to increased expression of the cyclin-dependent kinase inhibitor p27KIP1.

HNF-1α has been shown to trans-activate the rat insulin I gene promoter (9, 51). Overexpression of the SM6 and P291sinsC HNF-1α mutants in INS-1 insulinoma cells resulted in impaired insulin gene transcription (15, 28). Similar findings have been obtained by overexpression of a dominant-negative mutant of HNF-4α (52). Interestingly, insulin transcription is not completely suppressed in cells carrying a dominant-negative or null HNF-1α mutation (12, 28), suggesting that the insulin gene is also regulated by other transcription factors (11). The expression of insulin-like growth factors I and II is also reduced in HNF-1α-deficient mice (12). Defective insulin/insulin-like growth factor signaling through the PI 3-kinase and Akt kinase pathway may play a prominent role in DN-HNF-1α-induced apoptosis. Akt kinase is able to phosphorylate and inactivate several pro-apoptotic proteins, such as Bad and caspase-9 (53, 54). Other effects of PI 3-kinase and Akt kinase include phosphorylation-dependent regulation of transcription factors of the Forkhead and cAMP-response-element-binding protein families, leading to reduced transcription of pro- (55), and enhanced transcription of anti-apoptotic genes (56, 57). Interestingly, the Forkhead transcription factor FKHR-L1 has also been shown to down-regulate the expression of the cell cycle inhibitor p27KIP1 in a PI 3-kinase-dependent manner (58). Reduced insulin or insulin-like growth factor signaling through PI 3-kinase could therefore also play a role in the increase in p27KIP1 expression observed in the DN mutant cells. The PI 3-kinase/Akt kinase pathway has also been implicated in the activation of transcription factor nuclear factor-κB (NF-κB) (59, 60). Binding sites for the active NF-κB subunits p65/RelA and c-rel have been demonstrated by functional analysis of the bel-x promoter (61, 62). It is therefore conceivable that the reduction in Bcl-xL expression upon induction of DN-HNF-1α is caused by reduced activation of the PI 3-kinase/Akt kinase/NF-κB pathway. Overexpression of Bcl-xL in INS-1 cells potently inhibited DN-HNF-1α-induced apoptosis, demonstrating the importance of Bcl-xL in maintaining β-cell survival.

Bcl-xL inhibits apoptosis by preventing the release of pro-apoptotic factors from the mitochondrial intermembrane space into the cytosol (37). Bcl-xL may act to directly inhibit the formation of a megachannel in the outer mitochondrial membrane or may indirectly inhibit pore formation by neutralizing pro-apoptotic BHS-only family members. Although we detected Bax activation after the induction of DN-HNF-1α, the expression of Bax and Bak, as well as the expression of the BHS-only family members Bad, Bid, and Bim were unaltered. As a reduction in Bcl-xL expression may be per se sufficient to activate apoptosis (63, 64), our data point to an important role for HNF-1α in maintaining β-cell viability. The survival-supporting role of HNF-1α may not be confined to β-cells, as homogous HNF-1α knock-out mice also show increased degeneration.

Fig. 6. DN-HNF-1α sensitizes INS-1 cells to ceramide, but not to high glucose-induced cell death. A, expression of WT- or DN-HNF-1α was induced in the presence of 0–25 mM glucose for 24 or 48 h. Cytosolic protein extracts were prepared and caspase-3-like protease activity was measured using the fluorogenic substrate Ac-DEVD-AMC. Data are mean ± S.E. from n = 4 cultures. Difference in caspase activity from corresponding cultures exposed to 10 mM glucose: *, p < 0.05. Difference between WT- and DN-HNF-1α-induced INS-1 cells at identical glucose concentrations: #, p < 0.05. n.a., not analyzed. The experiment was performed in duplicate with similar results. B, effect on ceramide toxicity. Expression of WT- or DN-HNF-1α was induced for either 14 or 24 h. During the last 4 h, the culture medium was supplemented with C2-ceramide or vehicle (dimethyl sulfoxide), and a caspase activity assay was performed. Data are mean ± S.E. from n = 6 cultures. Different from non-induced controls: *, p < 0.05. A duplicate experiment yielded comparable results. C, expression of WT- or DN-HNF-1α was induced for 24 h. During the last 4 h, the culture medium was supplemented with 100 μM C2-ceramide, 100 μM C2-dihydroceramide or vehicle (dimethyl sulfoxide). Cells were stained live with Hoechst 33258 (detection of nuclear apoptosis) and propidium iodide (membrane leakage visualized by uptake of the membrane-impermeant dye propidium iodide) in response to C2-ceramide in living cells. Cells were induced to express WT- or DN-HNF-1α for 24 h. C2-ceramide (100 μM), the biologically less active C2-dihydroceramide (100 μM), or vehicle was added during the last 4 h. Exposure to C2-ceramide selectively induced apoptosis in the DN-HNF-1α-expressing cells (Fig. 6, C and D). Control experiments using C2-dihydroceramide showed that nonspecific detergent effects could be excluded.

DISCUSSION
of hepatocytes and defects in spermatogenesis (12). Moreover, the pathophysiological hyperpolarization of mitochondria observed after induction of DN-HNF-1α may also explain the reduced ability of glucose to hyperpolarize mitochondria and hence to stimulate and coordinate insulin secretion in these cells (15, 28).

Both an elevated glucose concentration as well as increased formation of free fatty acids have been suggested to contribute to a pathophysiological decline in β-cell mass by influencing β-cell proliferation and β-cell apoptosis (25, 65, 66). Exposure to high glucose has previously been shown to activate apoptosis in cultured mouse, rat, and human islets (66, 67). Expression of DN-HNF-1α-induced apoptosis over a broad glucose range (2–17.5 mM) compared with WT-HNF-1α-expressing cells. However, a potentiating effect of high glucose was not obvious in the DN-HNF-1α-expressing cells. In contrast, there was reduced apoptosis activation at 17.5 and 25 mM glucose. It is conceivable that increased bcl-xL mRNA expression at high glucose concentrations exerted a protective effect in the DN-HNF-1α-expressing cells.

WT-HNF-1α-expressing cells also activated apoptosis at 25 mM glucose (Fig. 6A), as did parental INS-1 cells. There was no statistically significant difference in the extent of apoptosis activation at 25 mM glucose between WT- and DN-HNF-1α-expressing cells. Our data therefore suggest that high glucose activates a cell death pathway that is not influenced by DN-HNF-1α. A recent study has shown that high glucose-induced apoptosis involved the activation of the death receptor pathway in β-cells via up-regulation of Fas receptor expression and activation of initiator caspase-8 (66). The activation of the mitochondrial pathway was unimportant as cytochrome c release could not be detected in response to high glucose. As shown in the present study, DN-HNF-1α activated the mitochondrial apoptosis pathway. Hence it is conceivable that high glucose and expression of DN-HNF-1α induce distinct cell death pathways.

In contrast, we observed a significant potentiation of zero glucose and in particular ceramide-induced apoptosis-overexpression of DN-HNF-1α. These findings suggest that these stimuli also induce the activation of the mitochondrial apoptosis pathway. Indeed, it has previously been shown that saturated fatty acids activate the mitochondrial apoptosis pathway (65), and that maintenance of Bcl-2 expression rescues β-cells from free fatty acid-induced apoptosis (25). Ceramide has been shown to impair insulin-induced signal transduction via the insulin-dependent membrane recruitment of Akt kinase (68). It is therefore conceivable that C2-ceramide and induction of DN-HNF-1α resulted in a potentiation of the inhibition of a central survival pathway. These results are also in accordance with the general role of HNF-1α in the control of lipid metabolism, and the β-cell protective effects of agents such as thiazolidinediones that influence lipid metabolism in animal models of NIDDM (25, 27, 69).

Previous studies in normal rats have demonstrated that a 96-h intravenous glucose infusion resulted in significant increases in β-cell mass due to neogenesis and hypertrophy (70) (see also Ref. 26). Interestingly, we observed decreased expression of the cell cycle inhibitor p27KIP1 at higher glucose concentrations in non-induced INS-1 cells. This adaptive response was still present, although reduced in cells overexpressing DN-HNF-1α. There is evidence for similar adaptive responses in prediabetic MODY3 subjects. After a 42-h glucose infusion resulting in mild hyperglycemia (~7 mM), there was a 32% increase in insulin secretion in MODY3 compared with control subjects (3). This adaptive response may not only be caused by an increase in β-cell proliferation, but also by an increased performance of individual β-cells. Prediabetic subjects with MODY 3 secrete adequate if not higher amounts of insulin at glucose levels ~8 mM (3) and may exhibit hyperexcitability to sulfonylureas (71). Nevertheless, it is tempting to speculate that mild hyperglycemia may to some extent exert protective effects in cells overexpressing DN-HNF-1α, by inhibiting p27KIP1 induction and stimulating Bcl-xL expression. Over time, however, accumulation of free fatty acids, increased ceramide generation, as well as additive effects of glucotoxicity may render β-cells more vulnerable to cell death. Likewise, in the Zucker diabetic fatty rat, β-cell proliferation compensates for the increased β-cell loss at a time when plasma glucose is moderately elevated, but this compensation ultimately fails and the plasma glucose levels increase further (27). An imbalance between β-cell death and neogenesis, in combination with decreased β-cell compensation for insulin resistance may eventually lead to diabetes in MODY3 patients.

Acknowledgments—We thank Christiane Schettler and Hanni Bihler for technical assistance, Drs. D. W. Nicholson and R. Cortese for their kind supply of antibodies, and Mrs. D. B. Thompson and L. H. Boise for Bcl-xL cDNA.

REFERENCES
Dominant-negative HNF-1α Induces Apoptosis

4621

1195–1205

27. Finegood, D. T., McArthur, M. D., Kojwang, D., Thomas, M. J., Topp, B. G.,

J. 17, 6701–6713

29. Nicolai, A., Monaci, P., Tomei, L., De Francesco, R., Nuzzo, M., Stunnenberg,


31. Smiley, S. T., Reers, M., Mottola-Hartshorn, C., Lin, M., Chen, A., Smith,
88, 3671–3675

789–801


34. Boone, L. H., Gonzalez-Garcia, M., Petestra, C. E., Ding, L., Lindsten, T.,


45. Bonferon, S. F., Medema, R. H., Pals, C., Banerji, L., Thomas, N. S., Lam, E. W.,
Burgering, B. M., Raujmakers, J. A., Lammers, J. W., Koendersman, L., and


50. Moczy, N., Wang, F., Rehl, K. A., Sawa, H., Nakayama, K., Negishi, I.,


52. Maedler, K., Spinas, G. A., Dyntar, D., Moritz, W., Kaiser, N., and Donath,


54. Krafka, A. R., Reynolds, D. A., Young, H. A., Thompson, C. B., Muecke, K.,

55. Poppe, M., Reimer, C., Lussch, M., Krohn, A. J., Luetjens, C. M.,
21, 4511–4565

37–49


58. Stennicke, H. R., Deveraux, Q. L., Humke, E. W., Reed, J. C., Dixit, V. M., and

Kastan, M. B., Griffin, D. E., Earnshaw, W. C., Velizoua, M. A., and


U. S. A. 89, 7300–7304


63. Datta, S. R., Dudek, H., Mao, X., Masters, S., Hu, H., Gotch, Y., and Greenberg,


67. Hansen, T., Eiber, H., Rouard, M., Vaxillaire, M., Moller, A. M., Rasmussen,
S. K., Fridberg, M., Urrhammer, S., Holst, J. J., Almind, K., Echwald,